Metronomic Dosing of Chemotherapy: Applications in Pediatric Oncology

REFERENCES

• Canadian Cancer Society. Statistics Canada, Provincial/Terretorial Cancer Registries, and Health Canada. Canadian Cancer Statistics 2004. National Cancer Institute of Canada
   Google Scholar
• Steen R. G. What is cancer?. Childhood Cancer: A Handbook from St. Jude Children's Research Hospital, G. Steen, J. Mirro. Perseus Publishing, Cambridge 2000; 3–10
   Google Scholar
• Baruchel S., Rowell M. Pharmacology of cancer chemotherapy in paediatrics: feasibility and ethical considerations in phase I trials. Paediatric Pharmacology: Towards Evidence-Based Drug Therapy, G. Koren, O. Diav-Citrin. Bailliere Tindall, London 1998; 439–453
   Google Scholar
• Canadian Cancer Statistics. Canadian Cancer Statistics 2000—Cancer in Children aged 0–19 years. Cancer Statistics 2000. National Cancer Institute of Canada, TorontoCanada 2000, Accessed June 22nd, 2005. Online: http://www.cancer.ca/stats2000.childe.htm
   Google Scholar
• Capizzi R. L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin. Oncol. 1999; 26: 3–21, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Blatt J., Copeland D. R., Bleyer W. A. Late effects of childhood cancer and its treatment. Principles and Practice of Pediatric Oncology, P. A. Pizzo, D. G. Poplack. Lippincott-Raven Publishers, Philadelphia 1997; 1303–1329
   Google Scholar
• Hahnfeldt P., Folkman J., Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol. 2003; 220: 545–554, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shimizu K., Oku N. Cancer anti-angiogenic therapy. Biol. Pharm. Bull. 2004; 27: 599–605, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Miller K. D., Sweeney C. J., Sledge G. W., Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 2001; 19: 1195–1206, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K. H., Augustin H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000; 60: 1388–1393, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D. J., Bohlen P., Kerbel R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000; 105: R15–R24, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Browder T., Butterfield C. E., Kraling B. M., Shi B., Marshall B., O'Reilly M. S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000; 60: 1878–1886, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285: 1182–1186, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990; 82: 4–6, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kerbel R. S., Kamen B. A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004; 4: 423–436, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kerbel R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31–36, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hida K., Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005; 65: 2507–2510, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005; 23: 939–952, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000; 105: 1045–1047, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kachel D. L., Martin W. J. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J. Pharmacol. Exp. Ther. 1994; 268: 42–46, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nuyts R. M., Pels E., Greve E. L. The effects of 5-fluorouracil and mitomycin C on the corneal endothelium. Curr. Eye. Res. 1992; 11: 565–570, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hoorn C. M., Wagner J. G., Petry T. W., Roth R. A. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol. Appl. Pharmacol. 1995; 130: 87–94, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Steiner R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. EXS 1992; 61: 449–454, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Yule S. M., Price L., McMahon A. D., Pearson A. D., Boddy A. V. Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin. Cancer Res. 2004; 10: 455–460, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Baguley B. C., Holdaway K. M., Thomsen L. L., Zhuang L., Zwi L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer 1991; 27: 482–487, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M. R., Viale G., Giavazzi R., Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996; 2: 1843–1849, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997; 57: 81–86, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lau D. H., Xue L., Young L. J., Burke P. A., Cheung A. T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 1999; 14: 31–36, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Presta M., Rusnati M., Belleri M., Morbidelli L., Ziche M., Ribatti D. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res. 1999; 59: 2417–2424, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Leary J. J., Shapiro R. L., Ren C. J., Chuang N., Cohen H. W., Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res. 1999; 5: 181–187, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Iyer S., Chaplin D. J., Rosenthal D. S., Boulares A. H., Li L. Y., Smulson M. E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 1998; 58: 4510–4514, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chaplin D. J., Pettit G. R., Hill S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999; 19: 189–195, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shaked Y., Emmenegger U., Man S., Cervi D., Bertolini F., Ben David Y., Kerbel R. S. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005, [CSA]
   Web of Science ®Google Scholar
• Beaudry P., Force J., Naumov G. N., Wang A., Baker C. H., Ryan A., Soker S., Johnson B. E., Folkman J., Heymach J. V. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005; 11: 3514–3522, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Funkhouser E. M., Sharp G. B. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116–1119, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bocci G., Francia G., Man S., Lawler J., Kerbel R. S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 12917–12922, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Colleoni M., Rocca A., Sandri M. T., Zorzino L., Masci G., Nole F., Peruzzotti G., Robertson C., Orlando L., Cinieri S., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 2002; 13: 73–80, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol. 2001; 2: 733–740, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kim E., Moore J., Huang J., Soffer S., Manley C. A., O'Toole K., Middlesworth W., Stolar C. J., Kandel J. J., Yamashiro D. J. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J. Pediatr. Surg. 2001; 36: 287–290, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Soffer S. Z., Kim E., Moore J. T., Huang J., Yokoi A., Manley C., O'Toole K., Middlesworth W., Stolar C., Yamashiro D., et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J. Pediatr. Surg. 2001; 36: 1781–1784, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Beppu K., Nakamura K., Linehan W. M., Rapisarda A., Thiele C. J. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. 2005; 65: 4775–4781, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Soffer S. Z., Moore J. T., Kim E., Huang J., Yokoi A., Manley C., O'Toole K., Stolar C., Middlesworth W., Yamashiro D. J., et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J. Pediatr. Surg. 2001; 36: 1177–1181, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McCrudden K. W., Yokoi A., Thosani A., Soffer S. Z., Kim E. S., Huang J., Manley C., O'Toole K., Yamashiro D. J., Kandel J. J., et al. Topotecan is anti-angiogenic in experimental hepatoblastoma. J. Pediatr. Surg. 2002; 37: 857–861, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gately S., Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog. Exp. Tumor Res. 2003; 37: 179–192, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Klement G., Huang P., Mayer B., Green S. K., Man S., Bohlen P., Hicklin D., Kerbel R. S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 2002; 8: 221–232, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bello L., Carrabba G., Giussani C., Lucini V., Cerutti F., Scaglione F., Landre J., Pluderi M., Tomei G., Villani R., et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 2001; 61: 7501–7506, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Sotomayor E. A., Huang Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992; 52: 6702–6704, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kakeji Y., Teicher B. A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15: 39–48, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cervi D., Klement G., Stempak D., Baruchel S., Koki A., Ben David Y. Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease. Clin. Cancer Res. 2005; 11: 712–719, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kakolyris S., Samonis G., Koukourakis M., Vlachonicolis I., Chalkiadakis G., Kalbakis K., Souglakos I., Agelaki S., Toloudis P., Georgoulias V. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am. J. Clin. Oncol. 1998; 21: 505–508, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., Tong W., Norton L., Spriggs D., Phase I. and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 1997; 15: 187–192, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Glode L. M., Barqawi A., Crighton F., Crawford E. D., Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643–1648, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nicolini A., Mancini P., Ferrari P., Anselmi L., Tartarelli G., Bonazzi V., Carpi A., Giardino R. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed. Pharmacother. 2004; 58: 447–450, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kieran M. W. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat. Res. 2004; 117: 337–349, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Shah M. A., Ilson D., Ramanathan R. K., Levner A., D'Adamo D., Schwartz L., Casper E., Schwartz G. K., Kelsen D. P. A Multicenter Phase II study of Irinotecan(CPT), Cisplatin(CIS), and Bevacizumab(BEV) in patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma. J. Clin. Oncol. 2005; 23: 4025, Abstr.[CROSSREF], [CSA]
   Google Scholar
• Garcia A. A., Oza A. M., Hirte H., Fleming G., Tsao-Wei D., Roman L., Swenson S., Gandara D., Scudder S., Morgan R. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J. Clin. Oncol. 2005; 23: 5000, Abstr.[CSA]
   Google Scholar
• Margolin J. F., Poplack D. G. Acute Lymphoblastic Leukemia. Principles and Practice of Pediatric Oncology, P. A. Pizzo, D. G. Poplack. Lippincott-Raven Publishers, Philadelphia 1997; 409–461
   Google Scholar
• Brugieres L., Quartier P., Le Deley M. C., Pacquement H., Perel Y., Bergeron C., Schmitt C., Landmann J., Patte C., Terrier-Lacombe M. J., et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children–a report from the French Society of Pediatric Oncology. Ann. Oncol. 2000; 11: 53–58, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baruchel S., Diezi M., Hargrave D., Stempak D., Gammon J., Moghrabi A., Coppes M., Fernandez C. V., Bouffet E. Safety and Pharmacokinetics of Temozolomide using a Dose Escalation Metronomic Schedule in Recurrent Pediatric Brain Tumors. European Journal of Cancer, In press[CSA]
   Web of Science ®Google Scholar
• Sterba J., Pavelka Z., Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002; 49: 117–120, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kuo D. J., Weiner H. L., Wisoff J., Miller D. C., Knopp E. A., Finlay J. L. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J. Pediatr. Hematol. Oncol. 2003; 25: 372–378, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Stempak D., Gammon J., Koren G., Baruchel S. Does metronomic chemotherapy combined with celecoxib provide anti-angiogenic therapy for pediatric recurrent solid tumors?. New Directions in Angiogenesis Research—an AACR Special Conference in Cancer Research. 2003, Abstr.
   Google Scholar
• Stempak D., Bukaveckas B. L., Linder M., Koren G., Baruchel S. CYP2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin. Pharmacol. Ther. 2005, in press[CSA]
   Web of Science ®Google Scholar
• Solomon S. D., McMurray J. J., Pfeffer M. A., Wittes J., Fowler R., Finn P., Anderson W. F., Zauber A., Hawk E., Bertagnolli M. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N. Engl. J. Med. 2005, [CSA]
   Web of Science ®Google Scholar
• Kamen B., Kieran M. Don't throw out the baby with the bathwater. J Pediatr. Hematol. Oncol. 2005; 27: 59–60, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Stempak D., Gammon J., Halton J., Champagne M., Koren G., Baruchel S. Modulation of celecoxib pharmacokinetics by food in pediatric patients. Clin. Pharmacol. Ther. 2005; 77: 226–228, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bowers D. C., Aquino V. M., Leavey P. J., Bash R. O., Journeycake J. M., Tomlinson G., Mulne A. F., Haynes H. J., Winick N. J. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. Pediatr. Blood Cancer 2004; 42: 93–98, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kebudi R., Gorgun O., Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr. Blood Cancer 2004; 42: 320–324, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jain R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001; 7: 987–989, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schneider M., Tjwa M., Carmeliet P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 2005; 7: 3–4, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shaked Y., Bertolini F., Man S., Rogers M. S., Cervi D., Foutz T., Rawn K., Voskas D., Dumont D. J., Ben David Y., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7: 101–111, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Maraveyas A., Lam T., Hetherington J. W., Greenman J. Can a rational design for metronomic chemotherapy dosing be devised?. Br. J. Cancer 2005; 92: 1588–1590, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kauffman R. E. Drug Therapeutics in the Infant and Child. Pediatric Pharmacology: Therapeutic Principles in Practice, S. J. Yaffe, J. V. Aranda. Saunders, Philadelphia 1992; 212–219
   Google Scholar
• Rodman J. H. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J. Adolesc. Health 1994; 15: 654–662, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kearns G. L., Reed M. D. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet. 1989; 1: 29–67, 17 Suppl[CSA]
   Google Scholar
• Blanco J. G., Harrison P. L., Evans W. E., Relling M. V. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos. 2000; 28: 379–382, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boreus L. O. Pharmacokinetics in Children. Principles of Pediatric Pharmacology, D. L. Azarnoff. Churchill Livingstone, New York 1982; 135–175
   Google Scholar
• Kerbel R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505–515, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Margolin K., Gordon M. S., Holmgren E., Gaudreault J., Novotny W., Fyfe G., Adelman D., Stalter S., Breed J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 2001; 19: 851–856, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Thomas J. P., Arzoomanian R. Z., Alberti D., Marnocha R., Lee F., Friedl A., Tutsch K., Dresen A., Geiger P., Pluda J., et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2003; 21: 223–231, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000; 5: 37–44, Suppl 1[INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Dosquet C., Coudert M. C., Lepage E., Cabane J., Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin. Cancer Res. 1997; 3: 2451–2458, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dirix L. Y., Vermeulen P. B., Pawinski A., Prove A., Benoy I., De Pooter C., Martin M., van Oosterom A. T. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer 1997; 76: 238–243, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bertolini F., Paolucci M., Peccatori F., Cinieri S., Agazzi A., Ferrucci P. F., Cocorocchio E., Goldhirsch A., Martinelli G. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br. J. Haematol. 1999; 106: 504–509, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Poon R. T., Fan S. T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001; 19: 1207–1225, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Byrne G. J., Ghellal A., Iddon J., Blann A. D., Venizelos V., Kumar S., Howell A., Bundred N. J. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J. Natl. Cancer Inst. 2000; 92: 1329–1336, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Poon R. T., Chung K. K., Cheung S. T., Lau C. P., Tong S. W., Leung K. L., Yu W. C., Tuszynski G. P., Fan S. T. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin. Cancer Res. 2004; 10: 4150–4157, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Feldman A. L., Tamarkin L., Paciotti G. F., Simpson B. W., Linehan W. M., Yang J. C., Fogler W. E., Turner E. M., Alexander H. R., Jr., Libutti S. K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin. Cancer Res. 2000; 6: 4628–4634, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lin R. Y., Argenta P. A., Sullivan K. M., Adzick N. S. Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients. Clin Cancer Res. 1995; 1: 327–331, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jeha S., Smith F. O., Estey E., Shen Y., Liu D., Manshouri T., Albitar M. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk. Res. 2002; 26: 399–402, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• de Bont E. S., Fidler V., Meeuwsen T., Scherpen F., Hahlen K., Kamps W. A. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin. Cancer Res. 2002; 8: 2856–2861, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tabone M. D., Landman-Parker J., Arcil B., Coudert M. C., Gerota I., Benbunan M., Leverger G., Dosquet C. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?. Clin Cancer Res. 2001; 7: 538–543, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pavlakovic H., Von S. V., Rossler J., Koscielniak E., Havers W., Schweigerer L. Quantification of angiogenesis stimulators in children with solid malignancies. Int. J. Cancer 2001; 92: 756–760, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hamano Y., Sugimoto H., Soubasakos M. A., Kieran M., Olsen B. R., Lawler J., Sudhakar A., Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004; 64: 1570–1574, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bocci G., Man S., Green S. K., Francia G., Ebos J. M., du Manoir J. M., Weinerman A., Emmenegger U., Ma L., Thorpe P., et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004; 64: 6616–6625, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Herbst R. S., Hess K. R., Tran H. T., Tseng J. E., Mullani N. A., Charnsangavej C., Madden T., Davis D. W., McConkey D. J., O'Reilly M. S., et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2002; 20: 3792–3803, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R. S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003; 63: 4342–4346, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., Kearne M., Magner M., Isner J. M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999; 85: 221–228, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J. M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18: 3964–3972, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2002; 2: 826–835, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001; 7: 1194–1201, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sikder H., Huso D. L., Zhang H., Wang B., Ryu B., Hwang S. T., Powell J. D., Alani R. M. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003; 4: 291–299, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Padera T. P., Stoll B. R., So P. T., Jain R. K. Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions. Mol. Imaging 2002; 1: 9–15, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schuch G., Heymach J. V., Nomi M., Machluf M., Force J., Atala A., Eder J. P., Jr., Folkman J., Soker S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 2003; 63: 8345–8350, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Willett C. G., Boucher Y., di Tomaso E., Duda D. G., Munn L. L., Tong R. T., Chung D. C., Sahani D. V., Kalva S. P., Kozin S. V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004; 10: 145–147, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658–3661, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Monestiroli S., Mancuso P., Burlini A., Pruneri G., Dell'Agnola C., Gobbi A., Martinelli G., Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001; 61: 4341–4344, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gill M., Dias S., Hattori K., Rivera M. L., Hicklin D., Witte L., Girardi L., Yurt R., Himel H., Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 2001; 88: 167–174, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Asahara T., Murohara T., Sullivan A., Silver M., van der Z. R., Li T., Witzenbichler B., Schatteman G., Isner J. M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–967, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lin Y., Weisdorf D. J., Solovey A., Hebbel R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 2000; 105: 71–77, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Capillo M., Mancuso P., Gobbi A., Monestiroli S., Pruneri G., Dell'Agnola C., Martinelli G., Shultz L., Bertolini F. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin. Cancer Res. 2003; 9: 377–382, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sussman L. K., Upalakalin J. N., Roberts M. J., Kocher O., Benjamin L. E. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol. Ther. 2003; 2: 255–256, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Beerepoot L. V., Mehra N., Vermaat J. S., Zonnenberg B. A., Gebbink M. F., Voest E. E. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol. 2004; 15: 139–145, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rabascio C., Muratori E., Mancuso P., Calleri A., Raia V., Foutz T., Cinieri S., Veronesi G., Pruneri G., Lampertico P., et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA. in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004; 64: 4373–4377, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 2000; 105: 17–19, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001; 7: 1194–1201, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bolontrade M. F., Zhou R. R., Kleinerman E. S. Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. Clin. Cancer Res. 2002; 8: 3622–3627, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shirakawa K., Furuhata S., Watanabe I., Hayase H., Shimizu A., Ikarashi Y., Yoshida T., Terada M., Hashimoto D., Wakasugi H. Induction of vasculogenesis in breast cancer models. Br. J. Cancer 2002; 87: 1454–1461, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bergers G., Benjamin L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003; 3: 401–410, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bocci G., Tuccori M., Emmenegger U., Liguori V., Falcone A., Kerbel R. S., Del Tacca M. Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann. Oncol. 2005, [CSA]
   PubMed Web of Science ®Google Scholar
• Marshal J. L., Rizvi N. A., Bhargava P., Wojtoqicz-Praga S., Hawkins M. J. New Developmental Therapies. Clinical Oncology, M. D. Abeloff. Churchill Livingstone, Inc. 2000; 242–251, Chapter 12
   Google Scholar
• Shusterman S., Maris J. M. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005, [CSA]
   PubMed Web of Science ®Google Scholar
• Emmenegger U., Man S., Shaked Y., Francia G., Wong J. W., Hicklin D. J., Kerbel R. S. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004; 64: 3994–4000, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Su Y. B., Sohn S., Krown S. E., Livingston P. O., Wolchok J. D., Quinn C., Williams L., Foster T., Sepkowitz K. A., Chapman P. B. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. 2004; 22: 610–616, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Su Y. W., Chang M. C., Chiang M. F., Hsieh R. K. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol. 2005; 71: 315–318, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McDonald D. M., Choyke P. L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 2003; 9: 713–725, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cristofanilli M., Charnsangavej C., Hortobagyi G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov. 2002; 1: 415–426, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Morgan B., Thomas A. L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M. A., Mross K., Ball H. A., Lee L., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003; 21: 3955–3964, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar